Regeneron Pharma Eylea HD injection approved by USFDA for treatment of Wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy Ruchika Sharma21 Aug 2023 1:30 PM ISTTarrytown: Regeneron Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD...
Regeneron Pharma secures USFDA okay for Veopoz for children, adults with Chaple disease Ruchika Sharma19 Aug 2023 11:40 AM ISTVeopoz, a fully human monoclonal antibody, is designed to target complement factor C5, a protein involved in complement system activation.
US FDA declines to approve Regeneron's higher dose Eylea Ruchika Sharma30 Jun 2023 11:00 AM ISTRegeneron was seeking approval for the drug to treat wet AMD, the leading cause of blindness among the elderly, and two eye diseases that are common...
Regeneron Pharma bags USFDA nod for Evkeeza for young children with ultra-rare form of cholesterol Ruchika Sharma23 March 2023 10:00 AM ISTHomozygous familial hypercholesterolemia occurs when two copies of the FH-causing genes are inherited, one from each parent, resulting in dangerously...
Regeneron Pharma gets USFDA nod for EYLEA Injection to treat preterm infants with retinopathy of prematurity Ruchika Sharma12 Feb 2023 3:00 PM ISTEYLEA is a VEGF inhibitor formulated as an injection for the eye.
Sanofi Dupixent gets European Commission nod for Prurigo Nodularis Ruchika Sharma18 Dec 2022 5:30 PM ISTParis: Regeneron Pharmaceuticals, Inc. and Sanofi have announced that the European Commission (EC) has expanded the marketing authorization for...
Regeneron Pharma Evkeeza under USFDA priority review for children with Ultra-rare inherited form of high cholesterol Ruchika Sharma4 Dec 2022 2:15 PM ISTTarrytown: Regeneron Pharmaceuticals, Inc. has announced the U.S. Food and Drug Administration (USFDA) has accepted for Priority Review the...
Regeneron Pharma, CytomX Therapeutics collaborate to create bispecific cancer therapies Ruchika Sharma20 Nov 2022 1:45 PM ISTCytomX will receive an upfront payment of $30 million and will be eligible to receive future target nomination payments and preclinical, clinical, and...
Regeneron gets six months of US pediatric exclusivity for Eylea injection Ruchika Sharma23 Oct 2022 3:30 PM ISTEYLEA is a VEGF inhibitor formulated as an injection for the eye
Sanofi to transfer 100 percent rights of Libtayo to Regeneron Ruchika Sharma3 Jun 2022 12:34 PM ISTUpon closing of the transaction, Regeneron will make an upfront payment of $900 million to Sanofi, which will be entitled to receive an 11% royalty on...
USFDA extends review of REGEN-COV to treat, prevent COVID-19: Regeneron Pharma Ruchika Sharma18 April 2022 10:00 AM ISTREGEN-COV (casirivimab and imdevimab) is a cocktail of two monoclonal antibodies designed specifically to block infectivity of SARS-CoV-2 using...
